The Floridian | Javier Manjarres | July 17, 2026
The Floridian recently covered Regenative Labs’ lawsuit against the U.S. Food and Drug
Administration, examining the company’s effort to obtain action on its long-pending applications
for Certificates to Foreign Government (CFGs), which are required to export certain
U.S.-manufactured medical products to international markets.
The article explains that the case reflects broader concerns about how regulatory delays can
impact American manufacturers, particularly small and mid-sized companies seeking to compete
globally. It also notes that many in the life sciences industry believe the current administration
has signaled a more responsive approach to reducing regulatory backlogs and supporting domestic
manufacturing.
A Florida biotech company is asking a federal court to require the U.S. Food and Drug
Administration (FDA) to act on long-pending export applications, arguing that delays dating back
to the Biden administration have prevented the company from competing internationally and
expanding its American operations.Regenative Labs says it hopes the current administration will bring greater clarity and
predictability to the process while allowing innovative American companies to compete globally.While the dispute centers on export certificates, it also reflects a broader debate in Washington
over how regulatory delays can affect American manufacturers, particularly small and mid-sized
companies seeking to expand into international markets.
The article also highlights the broader economic impact the delays have created.
The company argues that the unresolved applications have effectively prevented it from exporting
products to overseas markets, limiting growth opportunities and delaying planned investments in
U.S. manufacturing.‘Small businesses like ours deserve a fair, predictable, and timely regulatory process,’
CEO Tyler Barrett said. ‘Decisive FDA action on our applications will allow us to serve
patients around the world and add jobs in the U.S.’For Regenative, the outcome could extend well beyond access to foreign markets. Company leaders
say obtaining the export certificates would allow the Pensacola-based manufacturer to expand
production, invest further in its Florida operations, create hundreds of additional American
jobs, and bring U.S.-developed biotechnology products to physicians and patients around the world.